• Introduction to Lung Cancer
    • Introduction to Lung Cancer

      Lung cancer is one of the most threatening malignant tumors for human beings. According to the National Cancer Center's latest 2019 report, there were about 787,000 cases of new lung cancer in China (2015), with an incidence rate of 57.26 per 100,000 which ranks it as one of the cancers with the highest morbidity and mortality rates in China.
      Molecular classification based on lung cancer-driven genetic variation can help patients to choose individualized treatment options for precise treatment.

      Product Overview:
      Product Features:
      Suitable Patient Profile:
  • Significance of Gene Testing in Lung Cancer
    • Significance of Gene Testing in Lung Cancer

      The NCCN guidelines recommend molecular testing of gene EGFR, ALK, BRAF, MET, RET, ROS1, HER2 and NTRK to guide targeted therapy in patients with non-small cell lung cancer (NSCLC), and TMB was also added to guide immunotherapy for them.
      Genomic testing is essential for patients with lung cancer. Multi-gene testing can better guide the targeted treatment and immunotherapy, evaluate the curative effect and prognosis, carry out drug resistance monitoring, recurrence and metastasis monitoring for lung cancer patients.

      Product Overview:
      Product Features:
      Suitable Patient Profile:
  • Genetron in Lung Cancer Testing
    • Genetron in Lung Cancer Testing

      Immunization Integration Project

      Product Overview:
      Product Features:
      Suitable Patient Profile:
  • Genetron’s Genomic Testing Service for Lung Cancer
    • 18 genes lung cancer (tissue/blood)
      Product Overview:

      Based on advanced targeted capture technology and NGS sequencing platform, 18 high frequency variation related genes of lung cancer in Chinese population can be detected to guide the targeted treatment of lung cancer patients

      Product Features:

      1. Cover 108 species of drugs including targeted drugs for lung cancer, recommended drugs for NCCN guidelines and drugs for clinical trial

      2. Add genes related to the prognosis of curative effect so as to provide information for the selection and monitoring of treatment options for patients

      3. Cover 28 chemotherapy sites and analyze 21 mainstream chemotherapy drug regimens in order to provide guidance for patients choosing chemotherapy regimens

      Suitable Patient Profile:

      NSCLC patients who seek the guidance of targeted medication at the initial stage and NSCLC patients who need the guidance of adjuvant medication after II-IIIA surgery

    • 180 genes lung cancer testing (tissue/blood)
      Product Overview:

      Based on advanced targeted capture technology and NGS sequencing platform, a comprehensive test of 180 lung cancer related genes can provide accurate reference information for clinical precision targeted drug matching, molecular division, drug resistance monitoring, prognosis assessment, curative effect and recurrence monitoring, immunotherapy guidance, etc.

      Product Features:

      1. Full coverage of drug target genes to provide more opportunities for patient target drug matching or participation in clinical trials

      2. Comprehensive and real-time dynamic monitoring of recurrence and metastasis as well as the mechanism of molecular change in drug-resistant patients, so as to achieve the full course of lung cancer monitoring and management


      Suitable Patient Profile:

      Advanced NSCLC patients seeking more treatment opportunities as well as II-IIIA-stage NSCLC patients seeking postoperative adjuvant therapy

    • Onco PanScan™️ (tissue/blood)
      Product Overview:

      Combined with Genetron’s universal tumor database, the solid tumor 825 genes testing covers an updated version of the WHO, NCCN, ESMO and other authoritative guidelines and expert consensus recommended test genes. Based on the high-throughput, highly sensitive NGS platform and 'hybrid capture' technology, solid tumor 825 genes testing can provide multi-dimensional immunotherapy related biomarker detection (TMB, MSI, PD-L1, immune efficacy related gene variation), so as to guide the individualized diagnosis and treatment of tumor patients more accurately, It also provides more comprehensive reference information for researchers.

      Product Features:

      1. Focus on 238 tumor drugs, covering 12 classic tumor signaling pathways, 45 chemotherapy drug related sites, 90 immunotherapy related genes, 149 tumor genetic susceptibility genes

      2. Comprehensive and real-time dynamic monitoring of recurrent metastasis and the mechanism of molecular change in drug-resistant patients, to achieve the full course of cancer monitoring and management

      3. Multi-dimensional immunotherapy assessment


      Suitable Patient Profile:

      Tumor patients seeking more opportunities for targeted drugs or immunotherapy

  • Assessment Process
    • Assessment Process
      Product Overview:
      Product Features:
      Suitable Patient Profile:
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Verification code:
Genetron Health Genetron Health Management